Skip to main content
. 2015 Jan 12;33(12):1325–1333. doi: 10.1200/JCO.2014.57.4244

Fig 4.

Fig 4.

Carbohydrate antigen 19-9 (CA 19-9) responses. (A) CA 19-9 kinetics; in patients with abnormal baseline tumor marker CA 19-9 (> 37 U/mL), the following definitions to distinguish stable or responding (SR) from progression (PR) were used1: SR if < 50% increase for all assessments through 120 days,2 and PR if ≥ 50% increase in first 120 days for any assessment. (B) Overall survival based on CA 19-9 responses. HR, hazard ratio; N/A, not applicable.